Latest news with #RobertM.Davis
Business Wire
04-06-2025
- Business
- Business Wire
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Business Wire
22-05-2025
- Business
- Business Wire
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions Conference on Thursday, May 29, 2025 at 3:30 p.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Epoch Times
29-04-2025
- Business
- Epoch Times
Merck Announces $1 Billion Investment in Delaware, 500 Full-Time Jobs
Pharmaceutical company Merck will invest $1 billion to build a 470,000 square-foot facility in Wilmington, Delaware, in a bid to boost domestic production, the company said in an April 29 The facility, located at the Chestnut Run Innovation & Science Park, is expected to create 'more than 500 full-time roles and roughly 4,000 construction jobs,' the company said. 'The laboratory component is expected to be fully operational by 2028, with production of investigational compounds anticipated to start by 2030. Potential further expansion of the site would create an additional 1,500 full-time roles and 26,000 construction jobs,' it said. The facility will comprise laboratory, manufacturing, and warehouse capabilities to aid the launch and commercial production of Merck's medical offerings. Specifically, the site will be able to manufacture Keytruda, the company's prescription drug used to treat multiple cancers. Merck said it intends to establish the facility as the 'future U.S. home' for manufacturing Keytruda for American patients. Related Stories 4/29/2025 4/28/2025 The Wilmington site is set to be located near Delaware and Pennsylvania universities, which the company said will help attract talented students and professionals, thus boosting community growth and development. Merck CEO Robert M. Davis said the Wilmington facility represents the company's 'continued commitment' to growing its investments in U.S. manufacturing. The site 'has the potential to create thousands of high-paying American jobs while ensuring that we can produce and distribute products close to patients right here in the U.S,' he said. According to Merck, since the 2017 Tax Cuts and Jobs Act under the first Trump administration, the company has invested more than $12 billion to boost U.S. manufacturing and research capabilities. Over the next four years, Merck intends to invest more than $9 billion. Last month, the company announced the completion of a $1 billion, 225,000 square-foot facility in Durham, North Carolina, to expand vaccine production. This investment has generated almost 4,000 construction jobs and 400 full-time roles, Merck said. By 2028, Merck estimates that its investments in the United States will create more than 37,600 construction-related employment opportunities. Multiple other pharma companies have announced U.S. investments in recent weeks. On April 22, Switzerland-based pharmaceutical company Roche Earlier, on April 10, Swiss pharma company Novartis revealed a plan to invest $23 billion over five years to boost manufacturing and research operations. President Donald Trump announced during an April 8 Once tariffs are executed, pharma companies are 'gonna come rushing back into our country because we are the big market,' he said. Importing pharmaceuticals will become more expensive once tariffs are implemented, and it would make more sense for companies to shift production to the United States and avoid the extra charges. 'The advantage we have over everybody is that we are the big market. So, we're going to be announcing, very shortly, a major tariff on pharmaceuticals. And when they hear that, they will leave China, they will leave other places, because most of their products are sold here,' Trump said. On April 2, Trump The stock market declined post the announcement, but has made a partial recovery. The S&P 500 Tariff revenues are also up. An April 24 Treasury Billion-Dollar Accelerator On Monday, IBM announced it would On March 24, Hyundai Motor Group The investment 'is expected to create more than 100,000 direct and indirect job opportunities by 2028, including 14,000 direct full-time jobs,' the company said. On March 12, GE Aerospace On March 7, logistics company CMA CGM Group revealed a $20 billion The investments come amid the Trump administration's push to make the United States an attractive destination for companies. On March 31, Trump The USIA will encourage companies to make large investments in the United States through measures such as lowering regulatory burdens, increasing access to national resources, and speeding up permitting. Meanwhile, the Bureau of Economic Analysis is set to This would also be the first GDP quarterly decline since the first quarter of 2022. Market consensus suggests a 0.4 percent growth in the first quarter.
Yahoo
29-04-2025
- Business
- Yahoo
Merck to invest $1 billion in U.S. drug manufacturing plant
Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move comes amid plans by President Trump to impose tariffs on pharmaceuticals, which would include taxes on imported ingredients used in the making of such medicines. The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, the company's immunotherapy treatment for different cancers. The plant will be Merck's first U.S. facility dedicated to making Keytruda for U.S. patients, the company said. "This is part of a significant investment to not only bring the world's best-selling medicine closer to the American patients who rely on it, but to also establish a home for our biologics portfolio of products serving U.S. patients," Merck said in a statement Tuesday. The new site will spur growth in Wilmington's biotechnology sector, creating more than 500 full-time jobs, and roughly 4,000 construction jobs, the company said. The Wilmington lab is expected to be functional by 2028. "The Merck Wilmington Biotech site represents our continued commitment to growing our investments in U.S. manufacturing and has the potential to create thousands of high-paying American jobs while ensuring that we can produce and distribute products close to patients right here in the U.S.," Merck chairman and CEO Robert M. Davis said in a statement. Since the 2017 Tax Cuts and Jobs Act, Merck has allocated more than $12 billion toward its domestic manufacturing footprint. "We are committed to continuing our efforts to stimulate economic growth in the U.S., allowing for the domestic production and distribution of medicines and vaccines to patients here and around the world," the company said. A long list of American corporations have announced new investments in U.S. manufacturing under Mr. Trump's broad-based tariff program. Computing giant IBM this week pledged to spend $150 billion on U.S. manufacturing capabilities to "fuel the economy." While not all of the companies with plans to grow their U.S. production facilities have cited Mr. Trump's tariffs as the motivating factor, the White House has touted such moves as furthering Mr. Trump's goal of reshoring manufacturing and stoking job-creation on home soil. The life of teen idol Bobby Darin Bill Belichick on a life in football Pope Francis laid to rest Sign in to access your portfolio
Yahoo
24-04-2025
- Business
- Yahoo
Merck's (NYSE:MRK) Q1 Sales Beat Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street's revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year's revenue to be around $64.85 billion, close to analysts' estimates. Its non-GAAP profit of $2.22 per share was 4% above analysts' consensus estimates. Is now the time to buy Merck? Find out in our full research report. Revenue: $15.53 billion vs analyst estimates of $15.29 billion (1.6% year-on-year decline, 1.6% beat) Adjusted EPS: $2.22 vs analyst estimates of $2.14 (4% beat) The company reconfirmed its revenue guidance for the full year of $64.85 billion at the midpoint Operating Margin: 61.5%, up from 35.7% in the same quarter last year Constant Currency Revenue rose 1% year on year (12% in the same quarter last year) Market Capitalization: $198.1 billion 'Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,' said Robert M. Davis, Chairman and CEO, Merck. With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck (NYSE:MRK) develops and sells prescription medicines, vaccines, and animal health products across oncology, infectious diseases, cardiovascular, and other therapeutic areas. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in research and development to create innovative, patent-protected drugs. Successful products can generate significant revenue streams over their patent life, and the larger a roster of drugs, the stronger a moat a company enjoys. However, the business model is inherently risky, with high failure rates during clinical trials, lengthy regulatory approval processes, and intense competition from generic and biosimilar manufacturers once patents expire. These challenges, combined with scrutiny over drug pricing, create a complex operating environment. Looking ahead, the industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing. A company's long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Merck grew its sales at a mediocre 5.9% compounded annual growth rate. This wasn't a great result compared to the rest of the healthcare sector, but there are still things to like about Merck. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Merck's annualized revenue growth of 5.1% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. Merck also reports sales performance excluding currency movements, which are outside the company's control and not indicative of demand. Over the last two years, its constant currency sales averaged 7.9% year-on-year growth. Because this number is better than its normal revenue growth, we can see that foreign exchange rates have been a headwind for Merck. This quarter, Merck's revenue fell by 1.6% year on year to $15.53 billion but beat Wall Street's estimates by 1.6%. Looking ahead, sell-side analysts expect revenue to grow 3% over the next 12 months, a slight deceleration versus the last two years. This projection is underwhelming and implies its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating margin is a key measure of profitability. Think of it as net income - the bottom line - excluding the impact of taxes and interest on debt, which are less connected to business fundamentals. Merck has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 23%. Analyzing the trend in its profitability, Merck's operating margin rose by 26.5 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 9.4 percentage points on a two-year basis. This quarter, Merck generated an operating profit margin of 61.5%, up 25.8 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Merck's EPS grew at a solid 8.8% compounded annual growth rate over the last five years, higher than its 5.9% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. We can take a deeper look into Merck's earnings quality to better understand the drivers of its performance. As we mentioned earlier, Merck's operating margin expanded by 26.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q1, Merck reported EPS at $2.22, up from $2.08 in the same quarter last year. This print beat analysts' estimates by 4%. Over the next 12 months, Wall Street expects Merck's full-year EPS of $7.79 to grow 16.4%. We were impressed by how significantly Merck blew past analysts' constant currency revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 1.3% to $79.73 immediately after reporting. Merck had an encouraging quarter, but one earnings result doesn't necessarily make the stock a buy. Let's see if this is a good investment. When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
